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Abstract. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia in the
elderly. Substantial evidence suggests a role for nutrition in the management of AD and especially suggests that interventions
with combinations of nutrients are more effective than single-nutrient interventions. The specific multi-nutrient combination
Fortasyn™Connect (FC), shown to improve memory in AD, provides phosphatide precursors and cofactors and is designed to
stimulate the formation of phospholipids, neuronal membranes, and synapses. The composition comprises nucleotides, omega-3
polyunsaturated fatty acids (n3 PUFA), choline, B-vitamins, phospholipids, and antioxidants. The current study explored the
protective properties of FC in a membrane toxicity model of AD, the amyloid- 1–42 (A42) infused rat, which shows reduced
exploratory behavior in an Open Field and impaired cholinergic functioning. To this end, rats were fed an FC enriched diet or a
control diet and five weeks later infused with vehicle or A42 into the lateral ventricle. Ten weeks post-infusion A42-rats fed
the FC diet showed increased membrane n3 PUFA and phosphatidylcholine content while they did not show the reductions in
exploratory behavior or in choline acetyltransferase (ChAT) and vesicular acetylcholine transporter (VAChT) immunoreactivity
that were seen in A42-rats fed the control diet. We conclude that FC protects the cholinergic system against A42-induced
toxicity and speculate that the effects of FC on membrane formation and composition might be supportive for this protective
effect. Based on these data a long-term intervention study was started in the prodromal stages of AD (NTR1705, LipiDiDiet,
EU FP7).
Keywords: Alzheimer’s disease, amyloid-, cholinergic markers, dietary intervention, dietary precursors, membrane, nutrition,
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INTRODUCTION
Alzheimer’s disease (AD) is the most common cause
of progressive cognitive impairment and dementia in
the elderly [1, 2]. Traditionally, AD is characterized
by the presence of amyloid plaques and neurofibril-
lary tangles in the brain. However, several lines of
evidence suggest that the progression of AD better
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correlates with the loss of synaptic membranes [3–6]
and synapses [7–9]. Although the exact cause of AD
is unknown, ample evidence indicates that nutrition
can reduce AD risk factors and suggests that nutrition
can play a role in the management of AD [10–14].
We [13, 15] and others [16–18] propose that specific
nutrients should be combined in order to be effec-
tive in the management of AD. Since AD progression
was shown to correlate with synaptic membrane and
synapse loss, a nutritional composition was designed
to stimulate the formation of membranes, neurites,
and synapses. The fundamental building blocks of
membranes are phospholipids [19] and can be syn-
thesized from the dietary precursors docosahexaenoic
acid (DHA), uridine, and choline by the CDP-choline
cycle or Kennedy cycle [20]. Providing additional
nutrients, such as the B-vitamins which facilitate the
biosynthesis of phosphatidylcholine (PChol) from hep-
atic phosphatidylethanolamine (PEth), can add to the
stimulation of phospholipid synthesis [11, 21]. The
specific combination of dietary precursors and cofac-
tors, Fortasyn™Connect (FC), designed to stimulate
the formation of phospholipids, neuronal membranes,
and synapses, consists of DHA, eicosapentaenoic acid
(EPA), uridine monophosphate (UMP), choline, folic
acid, vitamin B6, vitamin B12, ascorbic acid, -
tocopherol, selenium, and phospholipids (PChol and
phosphatidylserine). Recently, this nutritional inter-
vention was tested in a randomized double-blind
controlled clinical study and was shown to improve
memory in drug-naive mild AD patients [22]. Now,
we focus on whether this specific FC enriched diet can
offer protection against the membrane disturbing [23,
24] effects of amyloid- (A).
A key factor in the development of AD is the for-
mation of dense plaques in the patient’s brain which
primarily consist of A [25]. To date, the mechanisms
of A-induced neural dysfunction and subsequent
memory impairment are only partly understood and
subject to extensive study. However, a specific A
species, A1–42 (A42) in its oligomeric conforma-
tion, is often considered as the primary pathogenic
agent in the onset of the amyloid cascade, eventually
resulting in a loss of synapses, neurites, and neuronal
membranes [26, 27]. It has been suggested that the
neurotoxic cascade of A is initiated at neuronal cell
membranes [28] and that membrane composition influ-
ences the level of A toxicity [29–31]. Adding to
this, an interesting and early characteristic [32] in the
development of AD that may be linked to neuronal
membrane degeneration is the profound reduction in
acetylcholine synthesis by choline acetyltransferase
(ChAT) [33–35]. The toxic effects of A42 on choliner-
gic parameters are well-studied through direct infusion
of A42 into the cerebrovascular system of rats or mice.
In the course of days to weeks after A42 infusion,
reductions can be observed in ChAT immunoreactive
neurons [36, 37], acetylcholine transport capacity as
visualized by reduced vesicular acetylcholine trans-
porter (VAChT) immunoreactivity [38], and reduced
exploratory behavior in a novel environment [39].
Based on these studies, we suggest that the A42 infu-
sion model may offer a method to study the effects of
preventive intervention on membrane-related damage
induced by A42 infusion.
Recently, we postulated that multi-nutritional inter-
vention may provide therapeutic potential in delaying
cognitive decline and AD [15]. Since intervention with
FC is intended to stimulate membrane formation and
to alter membrane composition, we speculate that this
may prevent the toxic effects of A42 on membrane
parameters as outlined above. To this end, rats fed the
FC enriched diet received an intracerebroventricular
A42 infusion and several weeks later the effect on
membrane characteristics and cholinergic parameters
in the magnocellular basal nucleus (NBM) was mea-
sured. In addition, exploratory behavior was assessed




Male Sprague Dawley rats (Charles River Neder-
land, The Netherlands) of 8 weeks of age at arrival
(4 groups of n = 8, 4 rats per cage) were housed in a
temperature- and light-controlled room (dark period:
7:00 h–19:00 h), with ad libitum access to food and tap
water throughout the experiment. All animal experi-
mental protocols were conducted in accordance with
international and national laws and institutional guide-
lines and approved by the local ethics committee (DEC
Consult, Bilthoven, The Netherlands).
Experimental staging
Figure 1 provides an overview of the staging of the
experiment. Before dietary intervention started, the rats
were housed until the age of 4½ months to become
adult. After 4 weeks of dietary intervention, surgery
was performed and 1 week later the rats were infused.
Ten weeks later the rats were tested in the Open Field
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Fig. 1. Overview of experimental staging. Animals arrived at the age of 8 weeks and were housed in a temperature- and light-controlled room
throughout the experiment. Start of dietary intervention was at the age of 19 weeks. Surgery and infusions were performed at respectively 23
and 24 weeks of age and the Open Field (OF) test was performed at 34 weeks of age where after the rats were sacrificed.
and thereafter sacrificed for brain collection. All pro-
cedures are described in more detail below.
Diets
Four weeks before surgery, rats were switched to
either the FC diet or the control diet. As indicated
in Table 1, the FC diet (Research Diet Services BV,
Wijk bij Duurstede, The Netherlands) was enriched
in omega-3 polyunsaturated fatty acids (n3 PUFAs)
(Loders Croklaan BV, Wormerveer, The Netherlands),
UMP (Mitsubishi International GmbH, Dusseldorf,
Table 1
Compositions of the experimental diets (g/100 g)




Soybean meal 8.5 8.5
Whey 5.0 5.0




L-lysine HCl 0.18 0.18
DL-methionine 0.05 0.05
Oil 5.0 5.0
C-18 : 1n9 1.13 0.83
C-18 : 2n6 (LA) 2.22 1.42
C-20 : 4n6 (AA) 0.00 0.04
total n6∗ 2.22 1.46
C-18 : 3n3 (ALA) 0.23 0.04
C-22 : 6n3 (DHA) 0.00 0.40
C-20 : 5n3 (EPA) 0.00 0.40
total n3∗ 0.23 0.96
UMP – 1.000
Soy lecithin – 0.400
Vitamin/mineral premix 2.20 2.20
Choline – 0.313
Folic acid – 0.00070
Vitamin B6 – 0.003
Vitamin B12 – 0.0000011
Vitamin C – 0.160
Vitamin E – 0.157
Selenium – 0.0001110
∗n3/n6 ratio 0.10 0.65
Germany), B-vitamins (Research Diet Services BV),
phospholipids (Cargill Texturant Solutions, Zaandam,
The Netherlands), choline (Research Diet Services
BV), and antioxidants (Research Diet Services BV)
compared to the control diet (Teklad standard lab
chow) (Harlan, Horst, The Netherlands). All diets were
prepared starting from the control diet. Barley was par-
tially replaced by the non-fat nutrients (e.g., UMP,
choline) while the PUFAs and phospholipids were
exchanged within the fat fraction of the diet using spe-
cific oil blends. All diets were iso-caloric and had the
same total fat content and the same level of PUFAs.
The diets were visually indistinguishable from each
other to secure blindness to treatment conditions.
Surgery
Four weeks after onset of dietary intervention
surgery was performed on all rats for placement of a
guide cannula above the right lateral ventricle. Rats
were anesthetized using an O2/N2O mixture with
2–3% isoflurane (InstruVet CV & AUV Dierenco-
operatie, Cuijk, The Netherlands) and were placed
in a stereotactic device (Kopf instruments, Tujunga,
CA). The skin on the head was exposed, cleaned with
alcohol and treated with lidocaine (MP Biomedicals
BV, Eindhoven, The Netherlands) as a local anes-
thetic. A longitudinal incision was made to expose
the skull and a small hole was drilled above the
right lateral ventricle (1.1 mm posterior and 1.6 mm
lateral to bregma). A stainless steel guide cannula
(Ø 0.6 mm, Netherlands Institute for Neuroscience,
Amsterdam, The Netherlands) was placed in the hole
projecting 2.5 mm into the brain and was secured to
the skull using cyanoacrylate. Three stainless steel
screws were inserted around the cannula to provide
extra grip for the dental cement. Cannula and screws
were secured with dental cement (Simplex Rapid, Den-
tal Union, Nieuwegein, The Netherlands) and the skin
was sutured to fit nicely around the dental cement cap.
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Once the animals recovered from the anesthetic, they
were transferred to their home cage.
Aβ42 infusions
Peptide preparation
A42 peptides were synthesized at the Department
of Medical Chemistry, University of Szeged, as it was
previously described [40] by a solid-phase procedure
involving Wang-resin and Fmoc chemistry. Crude pep-
tide was purified on a C-4 RP-HPLC column; pure
fractions were pooled and lyophilized. Purity control
was achieved by amino acid analysis (HP Amino Quant
amino acid analyzer) and mass spectrometry (ESI MS,
FinniganMat TSQ 7000).
Solution preparation
A42 solution was prepared by dissolving 200 g
in 100 l ultra-pure water. This solution was aged
for 2 h at room temperature before being used for
the infusions. This protocol results in an A solution
containing a mixture of A oligomers, protofibrils,
and fibrils. The aggregation grade of the colloidal A
solution was controlled by dynamic light scattering,
atomic force microscopy, and transmission electron
microscopy. All species were seen in the sample.
Freshly prepared A42 solutions were used for each
day of infusions.
Infusion paradigm
One week following surgery on three consecutive
days, an inner cannula was inserted into the guide
cannula projecting into the lateral ventricle (3.5 mm
below the dura) and connected to a 10 l syringe using
PEEK-tubing (PK005-020, Western Analytical Prod-
ucts, Murrieta, CA). Over a 10 min period, 3 l of
A42 solution was infused using a precision syringe
pump (PHD 2000, Harvard Apparatus Inc., Holliston,
MA) and afterward a 5 min pause was applied before
removal of the cannula from the guide. The animals
from each dietary intervention group were divided into
2 groups of 8 rats, one group receiving A42 infu-
sions and the other saline (Sham). Rats in the A42
group received a total of 20 g A42 during the three
infusions.
No complications were seen as a consequence of
surgery, although 4 Sham animals in the control diet
group and 1 in the FC diet group died 1 day after the
last infusion was administered. Section was performed
on these animals but cause of death remains unknown.
The remainder of the animals (27 in total) did not show
any complications.
Exploratory behavior
To measure exploratory behavior of the rats, we
subjected them to a 15 min Open Field (OF) session;
longer sessions would be more representative for base-
line activity [41]. Ten weeks post-infusion the rats were
placed in the OF during the dark period. The OF con-
sisted of a black, circular polyethylene arena (140 cm
in diameter) with a 50 cm high wall and was illumi-
nated with a 15 watt light bulb. Rats were placed in the
middle of the arena and were allowed to explore the
OF freely for 15 min. Walking patterns were observed
with a camera coupled to an automated tracking system
(EthoVision 3.1, Noldus, Wageningen, The Nether-
lands). As a second measure for exploratory behavior,
rearing frequency was also scored and was defined as
the number of times the rat stood erect on its hind-legs.
The OF was cleaned with 70% alcohol and allowed to
air-dry between successive animals.
Brain collection and processing
Fifteen weeks after onset of dietary intervention
and thus 10 weeks after A42 infusions, the ani-
mals were sacrificed at the age of 34 weeks. Rats
were anesthetized with an overdose of pentobarbi-
tal and transcardially perfused with ice-cold saline
(9 g/l NaCl) containing 5.8 mM EDTA (VWR Interna-
tional, Roden, The Netherlands). Brains were carefully
removed and split into the left and the right hemisphere.
The left hemisphere was snap frozen in liquid nitro-
gen and stored at –80◦C for fatty acid analyses. The
right hemisphere was placed in 4% paraformaldehyde
(Sigma-Aldrich Chemie, Zwijndrecht, The Nether-
lands) for 24–30 h before storage in PBS with 0.1%
azide at 4◦C (Sigma). Two weeks later, 30 m sec-
tions were cut using a vibratome and collected in 10
alternating series. The distance between two successive
slices within one series was approximately 300 m.
Slices were stored in PBS with 0.1% azide at 4◦C until
immunohistochemistry was performed.
Fatty acid analysis
Left hemispheres were used for phospholipid
and fatty acid analysis. Hemispheres were cut into
small pieces and homogenized with 2 ml water in a
Potter tube. The homogenate was vortexed for 5 min
with 2 ml methanol, 1 ml EDTA, and 1 ml dichloro-
methane. After 5 min, 1 ml EDTA and 1 ml dichloro-
methane were added and vortexed for 5 min then cen-
trifuged at 3000 rpm for 30 min. The dichloromethane
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layer (bottom layer) was transferred to a new
tube and 1 ml methanol was added, vortexed and
centrifuged for 10 min at 3000 rpm. Thirty l of
the dichloromethane/methanol sample was injected
into the HPLC and the phosphatidylcholine, phos-
phatidylethanolamine, and phosphatidylserine frac-
tions were collected. The phospholipid fractions were
evaporated and after addition of 0.3 ml 20% boron
trifluoride-methanol complex (VWR International) in
methanol, they were placed under a nitrogen atmo-
sphere at 100◦C for 60 min (methylation). After
cooling, the samples were vortexed with 2 ml hex-
ane and 1 ml 2.5 M NaOH for 2 min. The top layer
(hexane fraction) was transferred to a new tube and
evaporated under a nitrogen flow. The residue was dis-
solved in 80 l iso-octane, transferred to a glass insert
and fatty acid composition was analyzed in a gas chro-
matograph (column: CP-SIL88 (for FAME analysis)
50 m×0.25 mm id. 0.22 m film thickness (Varian)
Cat. no. 7488). Areas under the curve were taken as
relative measures of brain fatty acid and phospholipid
content.
Immunohistochemistry
Free-floating sections from 2 successive series were
stained for ChAT (1 : 500, Chemicon International,
Temecula, CA, Cat. no. AB144P) or VAChT (1 : 4000,
Chemicon International, Cat. no. AB1578). Antigen
retrieval was necessary for VAChT immunohistochem-
istry. To this end, sections were incubated in 0.01
M sodium citrate buffer in a water bath at 80◦C.
After 20 min, sections were allowed to cool to room
temperature. The next steps were identical for ChAT
and VAChT staining. Briefly, sections were incubated
with 0.3% hydrogen peroxide for 10 min to eliminate
endogenous peroxidase activity. Sections were incu-
bated overnight at room temperature with primary
antibodies for ChAT or VAChT. The sections were
subsequently incubated with biotinylated rabbit anti-
goat IgG (Bio-Connect B.V. - Vector Laboratories,
Huissen, The Netherlands) for 2 h followed by 1.5 h
incubation with ABC (avidin-biotin complex, ABC
Elite, Vector, Burlingame, CA). Sections were rinsed
between all steps with TBS three times for 10 min
each. The peroxidase reaction was developed in 0.05%
diaminobenzidine (DAB) (Sigma) and 0.01% H2O2
until a dark brown reaction product was evident. Sec-
tions were rinsed in TB and mounted on 1% gelatinized
slides, dehydrated and cover slipped in Entellan (VWR
International).
Image collection
VAChT sections were matched to those of one ani-
mal to locate comparable series of sections in all
animals. ChAT stained sections of the adjacent series
were matched with their counterparts from the VAChT
staining. Digital grayscale overview images of the
NBM at 5× magnification were taken at a standard
background of 32 on a scale of 0 to 255 (0 being
white and 255 being black) followed by 20× magni-
fication image collection for the analyses using Scion
Image (Scion Corporation, MD). Slices with VAChT
staining required an additional step to increase contrast
between background and stained cells and fibers using
a DAB filter. The NBM was identified in 8 slices in the
series of which five successive images were selected
for analyses starting approximately around the first
appearance of the hippocampus at bregma −0.80 and
then at −1.30, −1.60, −1.88, and −2.30 (see Fig. 2)
[42]. The surface areas of the NBM in these slices did
Fig. 2. Localization of the region of interest for ChAT and VAChT analyses. Location of the 5 successive images of the NBM used for the
analyses of the ChAT and VAChT staining according to the Paxinos brain atlas [42]. The region of the NBM measured is indicated by the square.
Images for each animal were related to these coordinates in order to match the images between animals.
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not differ between groups. All images were filed to
perform image analyses at a later stage.
Image analysis
The numbers of ChAT and VAChT immunoreactive
neurons were counted in the NBM using an auto-
mated routine in Scion Image. To identify the cells,
a threshold of gray value was determined. All pixel
groups above this threshold were counted as cells.
Because ChAT and VAChT stainings were very dif-
ferent in intensity, two different threshold values were
employed. The thresholds were calculated using a ref-
erence area within each section lacking stained cell
bodies. The average grayscale of these areas plus three
times the standard deviation was used as threshold
value. Using this method the threshold was calculated
to be 150 for ChAT and 70 for VAChT on a scale of 0
to 255. Structures exceeding this threshold and larger
than 3 pixels for ChAT sections or 15 pixels for VAChT
sections were counted as cells. The number of cells
per animal was determined by counting the numbers
of cells of all five images per animal.
Statistical analyses
Throughout the experiment the animals and diets
were coded to make the observers blind to the treatment
of the rats. The codes were unblinded after analyses
had been completed. All data were analyzed using
SPSS 15.0 (SPSS Inc., Chicago, IL). The current study
tested the influence of two factors and their inter-
action on brain phospholipid and fatty acid levels,
on exploratory behavior and on cholinergic mark-
ers. With this respect, dietary intervention is taken
as Factor 1 and A42 infusion as Factor 2. All sta-
tistical analyses tested for Factor 1 (Diet), Factor 2
(A42) and for Factor 1 * Factor 2 interaction effects
(Diet * A42) using ANOVA wherein p values <0.05
were considered significant. When ANOVA revealed a
significant Factor 1 * Factor 2 interaction effect post-
hoc analyses were performed to detect between group
differences.
Specifically for the analyses of the effects on brain
phospholipid and fatty acid content it was expected that
FC intervention would lead to increased brain phos-
pholipid levels, increased DHA, decreased AA and
increased n3/n6 PUFA ratio, while no effect of A42
infusion was expected. Therefore, ANOVA p-values
for Factor 1 and for Factor 2 effects were divided by 2
to allow for one-tailed analysis of the effects on brain
phospholipid and fatty acid contents.
RESULTS
Statistics
The overall statistical analysis results are presented
in Table 2. Post-hoc analyses were performed for the




Main effects Interaction effects
Group 1 (Diet) Group 2 (A42) Diet * A42
Phospholipids$ Total PL F = 1.60, p = 0.109 F = 0.049, p = 0.41 F = 0.019, p = 0.892
PChol F = 3.07, p ≤ 0.05 * F = 0.048, p = 0.42 F = 0.060, p = 0.809
PEth F = 0.718, p = 0.204 F = 0.50, p = 0.44 F = 0.035, p = 0.854
PSer F = 1.529, p = 0.115 F = 0.43, p = 0.26 F = 0.050, p = 0.826
Fatty acids$ DHA F = 27.15, p ≤ 0.001 * F = 0.10, p = 0.38 F = 1.09, p = 0.31
AA F = 90.70, p ≤ 0.001 * F = 1.22, p = 0.14 F = 0.069, p = 0.79
n3/n6 ratio F = 250.53, p ≤ 0.001* F = 0.62, p = 0.22 F = 0.14, p = 0.71
Exploration Distance F = 1.68, p = 0.208 F = 0.64, p = 0.433 F = 3.56, p ≤ 0.03 *
Rearing F = 1.64, p = 0.213 F = 5.12, p ≤ 0.04 * F = 3.11, p ≤ 0.05 *
Cholinergic markers ChAT F = 6.41, p ≤ 0.02 * F = 0.88, p = 0.358 F = 4.71, p ≤ 0.02 *
VAChT F = 2.58, p = 0.123 F = 2.33, p = 0.141 F = 2.85, p = 0.062 #
Statistical analyses of all results with ANOVA showing the main factor 1 effects (diet intervention), main
factor 2 effects (A42 infusion) and factor 1 * factor 2 interaction effects (diet * A42). $Factor 1 and
factor 2 effects for the brain phospholipid and fatty acid content are showing the one-tailed p-values (values
out of ANOVA analyses divided by 2) based on the clear expectation that FC intervention would increase
phospholipid and fatty acid content. Total PL: total phospholipids; PChol: phosphatidylcholine; PEth:
phosphatidylethanolamine; PSer: phosphatidylserine; DHA: docosahexaenoic acid; AA: arachidonic acid.
p ≤ 0.05. #: nearly significant.
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Table 3
Post-hoc analyses results for exploratory and cholinergic markers.
Exploration Cholinergic markers
Distance Rearing ChAT VAChT
Control Sham versus Control A42 0.018* 0.052 # 0.032* 0.037$
FC Sham versus FC A42 0.633 0.248 0.485 0.918
Control Sham versus FC Sham 0.821 0.514 0.987 0.846
Control A42 versus FC A42 0.028* 0.008* 0.002* 0.033$
Control Sham versus FC A42 0.526 0.748 0.524 0.771
Control A42 versus FC Sham 0.012* 0.119 0.016* 0.032$
Post-hoc analyses showing group differences for exploratory and cholinergic markers. *p ≤ 0.05; #: nearly
significant; $ significance based upon nearly significant interaction effect.
Table 4
Relative brain phospholipid contents
Diet Total PL PChol PEth PSer
Sham A42 Sham A42 Sham A42 Sham A42
Control 19.5 ± 1.6 20.2 ± 1.5 5.8 ± 0.5 6.0 ± 0.2 11.8 ± 1.0 12.8 ± 1.2 1.9 ± 0.3 1.6 ± 0.1
FC 22.9 ± 4.3 24.5 ± 3.2 7.6 ± 1.4* 7.5 ± 0.9* 13.0 ± 2.2 14.8 ± 2.0 2.3 ± 0.7 2.1 ± 0.3
A main effect of FC diet Intervention on neuronal PChol level was observed. No effect of A42 infusion and no
interaction effect were found on neuronal membrane phospholipid levels. Values represent areas under the curve
after HPLC analysis (arbitrary units). Statistical analyses results are shown in Table 2. Total PL: Total phospholipids;
PChol: Phosphatidylcholine; PEth: Phosphatidylethanolamine; PSer: Phosphatidylserine. *p ≤ 0.05.
Table 5
Relative brain PUFA contents.
Diet DHA AA n3/n6 PUFA ratio
Sham A42 Sham A42 Sham A42
Control 16.6 ± 0.26 16.1 ± 0.37 9.0 ± 0.13 9.2 ± 0.09 1.03 ± 0.022 1.00 ± 0.032
FC 18.4 ± 0.60* 19.0 ± 0.43* 7.6 ± 0.23* 7.7 ± 0.09* 1.46 ± 0.020* 1.45 ± 0.029*
Intervention with the FC diet increased DHA, decreased AA and increased the n3/n6 PUFA ratio. A42 infusion had
no effect on these parameters and no interaction effect with dietary intervention was found. DHA: Docosahexaenoic
acid; AA: Arachidonic acid. Fatty acid content is presented as a percentage of total fatty acid content. Statistical
analyses results are shown in Table 2. Values represent means ± standard errors. *p ≤ 0.05.
Phospholipid content
Table 4 lists the relative levels of brain phos-
pholipids of Sham and A42 rats. ANOVA analyses
of phospholipid levels showed a Factor 1 effect
of FC intervention on phosphatidylcholine (PChol)
(F = 3.07, p ≤ 0.05). No Factor 1 effects were found for
levels of total phospholipid (F = 1.60, p = 0.109), phos-
phatidylethanolamine (PEth) (F = 0.718, p = 0.204)
and phosphatidylserine (PSer) (F = 1.529, p = 0.115).
Infusion with A42 (Factor 2) had no effect on
total phospholipid, PChol, PEth and PSer levels
(respectively F = 0.049, p = 0.41; F = 0.048, p = 0.42;
F = 0.50, p = 0.44 and F = 0.43, p = 0.26). No inter-
action effects between dietary intervention and
A42 infusion were observed (respectively F = 0.019,
p = 0.892; F = 0.060, p = 0.809; F = 0.035, p = 0.854
and F = 0.050, p = 0.826).
Fatty acid profile
Table 5 summarizes the effect of FC interven-
tion on fatty acid content of brain phospholipids.
ANOVA analyses revealed Factor 1 effects on DHA,
arachidonic acid (AA), and n3/n6 PUFA ratio. FC inter-
vention resulted in increased levels of DHA (F = 27.15,
p ≤ 0.001) decreased AA level (F = 90.70, p ≤ 0.001)
and an increased n3/n6 PUFA ratio (F = 250.53,
p ≤ 0.001). Brain phospholipid levels of EPA, the
other n3 PUFA added to the FC diet, were not
detectable. No effects of A42 infusions (Factor 2)
on the levels of DHA, AA, and the n3/n6 PUFA
ratio were detected (respectively F = 0.10, p = 0.38;
F = 1.22, p = 0.14 and F = 0.62, p = 0.22). No interac-
tion effects between with dietary intervention and A42
infusions were observed (F = 1.09, p = 0.31; F = 0.069,
p = 0.79; F = 0.14, p = 0.71, respectively).
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Fig. 3. Exploratory behavior in the Open Field. ANOVA analyses
revealed that exploratory behavior as illustrated by distance moved
and rearing frequency was influenced in the study (F = 3.56, p ≤ 0.03
and F = 3.11, p ≤ 0.05, respectively). A42 induced a decrease in
exploratory activity in rats fed the control diet as visualized by a
decrease in the distance moved (post-hoc: p = 0.018) and a decrease
in the total number of rearings (post hoc: p = 0.052). In contrast, no
difference between A42 and Sham rats fed the FC diet was observed
(post-hoc: p = 0.63 and p = 0.25, respectively). Compared to Sham
rats on the control diet no differences were found in Sham FC rats
(post-hoc: respectively p = 0.82 and p = 0.51) or A42 FC rats (post-
hoc: respectively p = 0.53 and p = 0.75) were found. Bars represent
means ± standard errors. *: p < 0.05.
Exploratory behavior
The effect of A42 infusion and FC intervention
on exploratory behavior is plotted in Fig. 3. No main
effect of diet intervention (Factor 1) was observed
on exploratory makers (distance moved: F = 1.68,
p = 0.208; rearing: F = 1.64, p = 0.213). A main Fac-
tor 2 effect (A42 infusion) on rearing was detected
(F = 5.12, p ≤ 0.04) while no effect on distance moved
was found (F = 0.64, p = 0.433). Factor 1 * Factor 2
interactions were found for both distance moved and
the number of rearings. Post-hoc analyses revealed
that A42 infused rats fed the control diet were the
only group differing from all the other groups show-
ing reduced exploratory behavior. See Table 3 for all
individual group comparisons.
Cholinergic markers
Figure 4 shows the effects of A42 infusion and FC
intervention on cholinergic markers. Representative
pictures for the ChAT and VAChT staining are shown
in Fig. 5. ANOVA analyses revealed a main effect of
diet intervention (Factor 1) on the cholinergic marker
ChAT (F = 6.41, p ≤ 0.02) but not on VAChT (F = 2.58,
p = 0.123). No main Factor 2 effects (A42 infusion)
on ChAT and VAChT were detected (respectively
F = 0.88, p = 0.358 and F = 2.33, p = 0.141). Factor 1
Fig. 4. ChAT and VAChT immunoreactivity in the NBM. Feed-
ing with the FC diet prevented the A42-induced decline in ChAT
and VAChT immunoreactive cells in the NBM. Factor 1 * Factor
2 interactions were found for ChAT (F = 4.71, p ≤ 0.02) and nearly
for VAChT (F = 2.85, p = 0.062). Post-hoc analyses revealed that
A42 infused rats fed the control diet showed reduced ChAT and
VAChT positive cells compared to the other groups. See Table 3 for
all individual group comparisons. Bars represent means ± standard
errors.
* Factor 2 interactions were found for ChAT (F = 4.71,
p ≤ 0.02) and nearly for VAChT (F = 2.85, p = 0.062).
Post-hoc analyses revealed that A42 infused rats fed
the control diet showed reductions in cholinergic mark-
ers compared to all other groups. See Table 3 for all
individual group comparisons.
DISCUSSION
The current study clearly shows that intracere-
broventricular injections of A42 result in reduced
exploratory activity and in reduced ChAT and VAChT
immunoreactivity in the NBM. Intervention with FC
prevented the A42-induced decline in exploratory
activity and the reductions in ChAT and VAChT
immunoreactivity while no effects of FC on these
parameters were seen in Sham animals. Furthermore,
FC intervention changed neuronal membranes by
increasing phospholipid content and increased the total
level of DHA, decreased AA and increased n3/n6
PUFA ratio.
The current effects of A42 confirm and extend ear-
lier findings with A infusions on exploratory activity
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Fig. 5. ChAT and VAChT staining in rat brain slices. Representative pictures of ChAT (top row) and VAChT (bottom row) immunoreactivity
in the NBM at 20x magnification are shown. The pictures clearly show that the NBM of A42 infused rats fed the control diet (A42 Control)
show fewer stained cells compared to the other groups for both ChAT as VAChT staining.
and the cholinergic system. Others have shown that,
irrespective of the route of administration or the frag-
ment used, A reduced the number of ChAT positive
neurons in the medial septum or NBM [36, 37, 43–47].
This reduction was also reflected in reduced ChAT
enzyme activity [47] and reduced acetylcholine trans-
port capacity [38], leading to reduced acetylcholine
synthesis and release [48]. The current findings provide
additional support for these effects of A on choliner-
gic neurons. The toxic effect of A is further illustrated
by the reduction in exploratory activity shown in the
Open Field, which has also been observed by others
[39, 49, 50]. It would be interesting to study the effects
of FC on A42 plaque formation especially since we
and others have shown A reductions as a result of
DHA intervention [51–55]. However, no detectable
A42 plaques were found in infused rat brains and
therefore FC effects on plaque formation could not be
studied in this model.
Dietary intervention with FC prevented A42-
induced cholinergic and behavioral decline. To date,
only a limited number of nutritional intervention stud-
ies have shown beneficial effects of individual nutrients
on the cholinergic system but these studies were
restricted to ChAT activity and immunoreactivity. In
aged rats, ChAT activity could be partly restored
by supplementation with -tocopherol [56]. In addi-
tion, supplementation with choline alfoscerate restored
ChAT activity levels [57] and ChAT immunoreactiv-
ity in aged rats [58]. Conversely, ChAT activity was
reduced in aged mice supplemented with choline [59],
while phosphatidylcholine supplementation to Dull
mice had no effect on ChAT activity in the cortex [60].
Furthermore, fatty acid enriched diets like a soybean-
oil diet or diets enrichment with alpha-linolenic or
linoleic acid had no effect on ChAT activity levels
in adult rats [61, 62]. Together, these studies do not
show clear beneficial effects of single nutrient interven-
tion on cholinergic system integrity. We postulated that
multi-nutritional intervention may prevent the toxic
effects of A42 on membrane parameters and indeed
we show in this paper that a multi-nutrient approach
with FC prevented A42-induced decline of the cholin-
ergic system markers ChAT and VAChT. Moreover,
FC intervention prevented the decline in exploratory
behavior induced by A42 infusions. These results
indicate that multi-nutrient intervention with FC can
protect the cholinergic system against the toxic effects
of A42 and in addition prevent the behavioral decline
that is associated with cholinergic cell damage.
A42 treated rats provided with FC displayed similar
levels of exploratory behavior and ChAT and VAChT
immunoreactivity compared to Sham rats. Two possi-
ble mechanisms may explain the effect of FC in A42
rats. First, the formation of ChAT and VAChT may be
increased and thereby counteract the toxic effects of
A42. Second, FC may protect cholinergic cells from
A42-induced toxicity by maintaining the membrane’s
functional integrity. The FC composition was designed
to enhance the formation of membrane phospholipids
and indeed, intervention with FC increased relative
levels of neuronal membrane PChol confirming the
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effects of DHA and UMP on phospholipid forma-
tion [63, 64]. Both the Sham and the A42 infused
rats showed comparable effects of FC intervention
on membrane formation and fatty acid composition.
Because of these comparable effects on neuronal mem-
branes and the fact that no differences in ChAT and
VAChT immunoreactivity were found between Sham
rats receiving the control diet or the FC diet, it appears
unlikely that the production of ChAT and VAChT is
directly influenced by FC. Rather, these data sug-
gest that the changes in membrane integrity induce
properties that protect the cholinergic system against
A42-induced toxicity. This is underscored by the fact
that A42 has membrane disrupting properties [65] by
binding to the membrane [30, 66] leading to membrane
fluidity reductions [67, 68] and membrane perfora-
tions [69–71]. The role of the membrane in A42
toxicity is even more emphasized by the differential
sensitivity to A42 between subpopulations of neu-
ronal cells either in cultures or in animal brains being
explained by distinctive differences in membrane bind-
ing of A42 [72]. In addition, inhibiting membrane
binding capacity of A42 itself demonstrated a lack of
toxicity in primary neuronal cultures [66]. Therefore,
we conclude that FC protects the cholinergic system
against A42-induced toxicity and speculate that the
effects of FC on membrane formation and composi-
tion might be supportive for this protective effect by
reducing the potential binding capacity of A42 to the
membrane thereby limiting the membrane disrupting
properties. These data support the suggestion that early
intervention with these specific brain-supportive nutri-
ents, in addition to improving memory in diagnosed
AD patients [22] may also prevent or delay cognitive
decline and AD [15].
The cholinergic system is affected in AD, with
decreases in acetylcholine as one of the more promi-
nent hallmarks, caused by a decrease in production
by the enzyme ChAT [73, 74]. The majority of cur-
rently available medical treatments for AD focus on
increasing levels of acetylcholine by preventing its
breakdown by acetylcholine esterase (AChE). Indeed,
studies show that treating AD patients with AChE-
inhibitors can increase acetylcholine levels and give
patients some relief from their symptoms [75, 76].
The present data indicate that nutritional intervention
may add value to current drug treatments by reduc-
ing the toxic effects of A42. Furthermore, based
(amongst others) on these data a long-term interven-
tion study was started in the early, prodromal stages of
AD (NTR1705, within the LipiDiDiet project, EU FP7
program) [77]. Primary outcome measure of the study
is cognitive performance but also focuses on develop-
ment of plasma biomarkers like A40 and A42.
In summary, our experiments show that interven-
tion with the FC enriched diet protected cholinergic
neurons in the basal forebrain against A42 toxicity,
affected neuronal membrane fatty acid composition
and phospholipid levels and in addition prevented the
decline in exploratory behavior seen in A42 infused
animals on a control diet. It is speculated that the
protective effects of FC may depend on improved
membrane integrity thereby limiting the membrane
binding and membrane disrupting properties of A42.
The data suggest that multi-nutrient intervention with
specific precursors and cofactors (Fortasyn™Connect)
may benefit AD patients by protecting cholinergic neu-
rons against A42-induced toxicity.
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